Silent celiac disease: who is tested when there are no symptoms
Short answer
Silent celiac disease is celiac disease found without symptoms7. The US Preventive Services Task Force found the evidence insufficient to weigh the benefits and harms of screening people with no symptoms1. The American College of Gastroenterology says testing of asymptomatic first-degree relatives of someone with celiac disease can be considered23, and Coeliac UK, a UK charity, says anyone with a close relative with coeliac disease should be tested41.
Part of Celiac diagnosis, testing and gluten sensitivity, 25 guides

Key points
- The Task Force’s 2017 statement is an “I” grade with “No recommendation”: it says the evidence is lacking, not that testing people without symptoms is wrong2, 3, 4.
- The American College of Gastroenterology recommends case finding in clinical practice and recommends against mass screening in the community20, 21.
- The NIDDK says US doctors do not routinely screen for celiac disease, and that blood relatives of people with celiac disease and people with type 1 diabetes should talk with their doctor about testing34.
- Symptoms alone miss people: the ACG guideline calls testing only those with classic symptoms insufficient to detect most persons with celiac disease25.
- The NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing, because the diet can affect test results36.
What “silent” celiac disease means
The Task Force describes celiac disease as varying in presentation, severity and natural history, and says that includes asymptomatic, or “silent”, disease6. In its words, silent celiac disease means positive histology findings but no symptoms7.
It is not the same as potential celiac disease, which the Task Force describes as positive serology findings with mild or no intestinal damage on biopsy7. A European guideline for adults uses the term “subclinical” for a similar situation: some patients are asymptomatic at diagnosis31.
What silent disease means for a person’s later health is not settled. The Task Force says the evidence is insufficient as to whether silent disease carries the same risks as symptomatic disease9.
What the Task Force said in 2017, and what it did not say
The Task Force’s final statement on celiac disease screening is dated March 28, 20172. It concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons1. The statement applies to adults, adolescents and children who do not have signs or symptoms of celiac disease5.
The Task Force found inadequate evidence for targeted screening of people at increased risk, such as those with a family history or other risk factors10. It also found inadequate evidence on treating screen-detected, asymptomatic disease, compared with no treatment or treatment started after a clinical diagnosis11.
An “I” statement is not a recommendation against testing. The Task Force’s clinician summary reads “No recommendation”3, and the statement says the evidence is lacking and the balance of benefits and harms cannot be determined4.
The page also reports that literature scans in May 2024 showed a lack of new evidence to support an updated systematic review12. We read the page on 2026-11-17; the Task Force can change it, so check the page for any later update.
The harms the Task Force names
Potential harms of screening people without symptoms include false-positive, inconclusive or unnecessary blood test results and biopsies, with possible anxiety or complications from testing13. The Task Force’s estimates: assuming a prevalence of approximately 1%, the positive predictive value of serologic testing is 12% to 40%14; in a higher-risk population it is 40% to 80%, depending on the test used and whether the assumed prevalence is 5% or 10%15.
The Task Force also lists overdiagnosis as a concern, since limited follow-up evidence shows some people diagnosed with celiac disease may never develop symptoms or complications16.
Which groups guidelines name for testing without symptoms
Screening everyone and testing groups with a higher chance of celiac disease are two different questions. The Task Force itself says screening is typically not performed in average-risk persons17, and lists a positive family history, with an estimated prevalence of 5% to 20%, among the factors that raise risk18.
| Source | What it says | Where it applies |
|---|---|---|
| American College of Gastroenterology (2023) | Recommends case finding in clinical practice and recommends against mass screening in the community20, 21. Says patients with a first-degree family member who has a confirmed diagnosis should be tested whether they show possible signs or symptoms or laboratory evidence of celiac disease22, and that testing asymptomatic relatives can be considered23. For type 1 diabetes: tested if there are suggestive symptoms or signs24. | US |
| NIDDK | US doctors do not routinely screen. Blood relatives of people with celiac disease and people with type 1 diabetes should talk with their doctor about whether to be tested34. | US |
| North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (as reported in the Task Force’s 2017 statement) | Recommends testing asymptomatic children with associated conditions or a first-degree relative with celiac disease, from around age 3 years, if they have eaten an adequate gluten-containing diet for at least 1 year before19. | North America, children |
| European Society for the Study of Coeliac Disease (2025) | Lists first-degree relatives of people with celiac disease, even if asymptomatic, and people with Down, Turner or Williams syndrome in a group that should be screened32. Type 1 diabetes and Hashimoto’s thyroiditis sit in a separate group that should be tested33. | Europe, adults |
| NICE, as summarised by Coeliac UK | Serological testing should be offered to people with type 1 diabetes or autoimmune thyroid disease at diagnosis and to first degree relatives of people with coeliac disease43. | UK |
Coeliac UK, a UK charity, says anyone with a close relative with coeliac disease should be tested, and that around 1 in 10 close relatives will be at risk41, 42. It also says that some factors can suggest coeliac disease even in someone who has no symptoms, and that testing people can help diagnose coeliac disease earlier40.
The groups differ from one guideline to the next. The ACG calls case finding the current preferred strategy for finding more cases, while the pros and cons are still a matter of debate30. Whether any of them applies to a particular person is a question for a clinician.
Why symptoms are a poor guide
The NIDDK says celiac disease is not diagnosed on symptoms alone, because some symptoms resemble those of other digestive disorders such as irritable bowel syndrome or lactose intolerance35. The ACG guideline says testing only people with classic symptoms (diarrhea and weight loss) is insufficient to detect most persons with celiac disease25.
Silent is also not always silent in hindsight. The ACG notes that people found through screening often have symptoms that were not previously explained, and others had symptoms that were not considered abnormal until after they started a gluten-free diet; screen-detected people with no symptoms remain without symptoms after starting the diet26.
What testing looks like when there are no symptoms
The ACG says serologic testing should measure tissue transglutaminase IgA (TTG IgA) while the person is eating a regular, gluten-containing diet, with a total IgA measurement if IgA deficiency has not been checked. It says patients with an elevated TTG IgA level should proceed to an upper endoscopy with duodenal biopsy29. The NIDDK likewise says doctors typically diagnose celiac disease with blood tests and biopsies of the small intestine37. The ACG also suggests a nonbiopsy strategy for selected children44.
The related guides below cover the blood test in detail.
Why testing comes before a gluten-free diet
The NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing, because the diet can affect test results36. The ACG guideline describes the antibody test as done on a regular, gluten-containing diet29.
What a positive result leads to
After an elevated blood test, the next step in the pathway described above is endoscopy with biopsy. Our related step-by-step diagnosis guide walks through that sequence.
Two findings sit side by side in the literature. The ACG reports that most people with celiac disease identified through screening reported dietary adherence and improved quality of life on a gluten-free diet28, and that a small proportion reported increased health-related anxiety after diagnosis27. The Task Force, in 2017, found inadequate evidence that treating screen-detected disease improves morbidity, mortality or quality of life, compared with no treatment or treatment started after clinical diagnosis11.
Family risk and gene tests
Every body in the table above names relatives of people with celiac disease. Our related genetics guides cover that risk in detail.
One point from the NIDDK bears on testing: having the DQ2 or DQ8 gene variants alone does not mean a person has celiac disease, and most people with them do not develop it38. Without these variants, celiac disease is very unlikely39.
Questions people ask
Is silent celiac disease the same as potential celiac disease?
No. The Task Force describes silent celiac disease as positive histology findings but no symptoms, and potential celiac disease as positive serology findings with mild or no intestinal damage on biopsy7.
Does silent celiac disease always become symptomatic?
The Task Force says data are limited on how many people with silent or potential celiac disease later develop symptoms7. It cites three long-term studies of US adults, followed for 10 to 45 years, that reported progression from positive serology findings (not specifically silent disease) to a clinical diagnosis in 0% to 15%8.
Does the Task Force say people without symptoms should not be tested?
No. Its 2017 statement is “I” (insufficient evidence), with no recommendation either way2, 3. Other bodies, such as the ACG, name groups for testing20, 23.
Do people found through screening feel better on a gluten-free diet?
The evidence is reported differently by different bodies. The ACG says most people identified through screening reported dietary adherence and improved quality of life on the diet28. The Task Force found inadequate evidence in 2017 on whether treating screen-detected, asymptomatic disease improves morbidity, mortality or quality of life11.
More in Celiac diagnosis, testing and gluten sensitivity
Celiac disease or IBS: overlapping symptoms and what guidelines say about testingWhat the ACG IBS guideline says about celiac blood tests, how the two conditions compare per NIDDK, and why celiac testing needs gluten in the diet.
Follow-up testing after a celiac diagnosis: what the guidelines listWhat celiac guidelines and charities list for follow-up: antibody checks, repeat biopsy, nutrient tests, and what is checked if symptoms continue.
Positive celiac blood test but a normal biopsy: what doctors call potential celiac diseaseWhat celiac guidelines say when antibodies are positive but the biopsy looks normal: potential celiac disease, other causes, and the follow-up described.
Wheat allergy tests vs celiac tests: which test answers which conditionWhich test answers which condition: celiac antibodies and biopsy versus wheat IgE, skin prick and food challenge, as ACG, NIAID, FARE and NIH say.
How a gluten challenge works before celiac testingWhat named celiac sources say about the amount and length of a gluten challenge before testing, side by side, and why a clinician plans it.
At-home celiac and gluten sensitivity tests: what they can and cannot showWhat home celiac antibody kits, IgG food panels, stool and genetic tests can and cannot show, and what a result still needs from a clinician.
All 25 guides in Celiac diagnosis, testing and gluten sensitivity
Related guides
Celiac Blood Tests: What tTG-IgA, Total IgA, DGP and EMA Each CheckWhat tTG-IgA, total IgA, EMA and DGP check, why total IgA is drawn with tTG-IgA, when back-up tests are used, and why gluten stays in the diet first.
Celiac genetic testing: what HLA-DQ2 and DQ8 results can and cannot tell youWhat HLA-DQ2 and DQ8 typing checks for, how NIDDK, ACG, ESPGHAN and WGO read a negative or positive result, and where the guidelines place the test.
Celiac disease symptoms in adults: what the sources list and who gets testedDigestive and non-digestive celiac symptoms as NIDDK, ACG and Coeliac UK list them, who guidelines say to test, and why gluten stays in the diet first.
How celiac disease is diagnosed, step by stepFrom blood test to biopsy or no-biopsy diagnosis: what US, European and UK guidelines say, where they differ, and what they say about eating gluten first.
Sources
- [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19] US Preventive Services Task Force, Celiac Disease: Screening (Final Recommendation Statement), checked Nov 17, 2026.
Read on 2026-11-17: the page is headed “Final Recommendation Statement”, “Celiac Disease: Screening”, dated March 28, 2017, and gives the grade as “I (insufficient evidence)”.
- [20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 44] American College of Gastroenterology (American Journal of Gastroenterology), ACG Guidelines Update: Diagnosis and Management of Celiac Disease (Rubio-Tapia et al., 2023), checked Nov 17, 2026.
- [31, 32, 33] European Society for the Study of Coeliac Disease (United European Gastroenterology Journal), ESsCD 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach, checked Nov 17, 2026.
Read on 2026-11-17: Table 2 has a group headed “Individuals who should be screened for CeD (high‐risk but asymptomatic or mildly symptomatic)”. It lists, under genetic conditions, Down syndrome, Turner syndrome and Williams syndrome, and, under family history, first‐degree relatives of individuals with CeD, even if asymptomatic.
Read on 2026-11-17: Table 2 has a group headed “Individuals who should be tested for CeD (symptomatic or associated conditions)”. Its endocrinological and autoimmune disorders row lists type 1 diabetes mellitus, Hashimoto's thyroiditis, Grave's disease and Sjögren's syndrome.
- [34, 35, 36, 37, 38, 39] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diagnosis of Celiac Disease, checked Nov 17, 2026.
- [40, 41, 42] Coeliac UK, Screening for coeliac: who should get tested?, checked Nov 17, 2026.
- [43] Coeliac UK, Who to Test for Coeliac Disease (healthcare professionals), checked Nov 17, 2026.
Read on 2026-11-17: the page says the National Institute for Health and Care Excellence (NICE) guideline states that serological testing should be offered to children and adults with any of the following signs and symptoms, and the list includes “Type 1 diabetes, at diagnosis”, “Autoimmune thyroid disease, at diagnosis” and “First degree relatives of people with coeliac disease”. A second list of people for whom NICE says to consider testing includes Down syndrome and Turner syndrome.